ReviewFrontiers in immunology2026
The active immune role of keratinocytes: from passive targets to key hubs in psoriatic inflammation.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a chronic immune-mediated inflammatory skin disease historically viewed as a disorder of keratinocyte hyperplasia, with subsequent recognition of central immune cell involvement. However, accumulating multi-omics and functional genomic evidence has reshaped this paradigm, positioning keratinocytes not merely as passive targets of immune attack but as active participants within a bidirectional epithelial-immune network that drives inflammatory initiation, maintenance, and amplification. This critical narrative review synthesizes the molecular mechanisms by which keratinocytes integrate genetic susceptibility, environmental triggers, metabolic reprogramming, and cell death programs to modulate psoriatic inflammation. We examine interleukin (IL)-1/IL-36 cytokines, the dual function of the antimicrobial peptide LL-37, danger signal release and dendritic cell recruitment, chemokine networks and exosome-mediated communication, the neuropeptide-keratinocyte axis, carbohydrate and lipid metabolic abnormalities, mitochondrial dysfunction and reactive oxygen species (ROS)-mediated feedback, epidermal barrier defects and microbiome dysregulation, diagnostic biomarkers, and therapeutic innovations. We further critically evaluate controversies, conceptual challenges, research gaps, and future directions. A keratinocyte-centric framework-situated within the broader context of epithelial-immune reciprocity-advances understanding of psoriasis pathogenesis and informs precision therapies targeting the barrier-immune axis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.